These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38252223)

  • 1. Meaningful score changes for SF-36v2, FACIT-fatigue, and RASIQ in rheumatoid arthritis.
    Rendas-Baum R; Lin X; Kosinski M; Bjorner JB; Bracher MG; Chen WH
    J Patient Rep Outcomes; 2024 Jan; 8(1):9. PubMed ID: 38252223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development, psychometric evaluation and cognitive debriefing of the rheumatoid arthritis symptom and impact questionnaire (RASIQ).
    Becker B; Bracher M; Chauhan D; Rendas-Baum R; Lin X; Raymond K; O'Connor M; Kosinski M
    J Patient Rep Outcomes; 2021 Dec; 5(1):129. PubMed ID: 34894330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
    Bartlett SJ; Bingham CO; van Vollenhoven R; Murray C; Gruben D; Gold DA; Cella D
    Arthritis Res Ther; 2022 Apr; 24(1):83. PubMed ID: 35382883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
    Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
    Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus.
    Rendas-Baum R; Chen WH; Gairy K; Anderson S; Henning C; Hammer A; Kosinski M
    Lupus Sci Med; 2024 May; 11(1):. PubMed ID: 38724182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
    Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
    RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
    Strand V; Burmester GR; Zerbini CA; Mebus CA; Zwillich SH; Gruben D; Wallenstein GV
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):475-83. PubMed ID: 25186034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data.
    Cella D; Johansson P; Ueda Y; Tomazos I; Gustovic P; Wang A; Patel AS; Schrezenmeier H
    J Patient Rep Outcomes; 2023 Jul; 7(1):63. PubMed ID: 37405515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
    Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
    Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic interventions for fatigue in rheumatoid arthritis.
    Almeida C; Choy EH; Hewlett S; Kirwan JR; Cramp F; Chalder T; Pollock J; Christensen R
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD008334. PubMed ID: 27271314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.